Entasis Therapeutics Funding: $122M Raised, Series B (2017)
Entasis Therapeutics is based in Waltham, MA. It has raised $122M in total funding. Latest round: Series B.
Entasis Therapeutics funding overview
Entasis Therapeutics is based in Waltham, MA. Entasis Therapeutics has raised $122M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in January 2017. The round record for Entasis Therapeutics runs through 2017; nothing later has been disclosed. Investors on record include AstraZeneca Clarus Ventures, Eventide Asset Management, Frazier Healthcare, Novo A/S, Sofinnova Ventures, TPG Biotech. 6 distinct backers are named across the disclosed rounds.
Entasis Therapeutics at a glance
Total raised
$122M
Latest round
Series B
Latest round date
January 2017
Headquarters
Waltham, MA
Notable investors
AstraZeneca Clarus Ventures, Eventide Asset Management, Frazier Healthcare, Novo A/S, Sofinnova Ventures, TPG Biotech
Frequently asked about Entasis Therapeutics funding
How much has Entasis Therapeutics raised?
Entasis Therapeutics has raised $122M in total disclosed funding across the rounds on record.
Who has invested in Entasis Therapeutics?
AstraZeneca Clarus Ventures, Eventide Asset Management, Frazier Healthcare, Novo A/S, Sofinnova Ventures, TPG Biotech are named among the investors backing Entasis Therapeutics.
What was the latest Entasis Therapeutics funding round?
The most recent disclosed round is a Series B, announced in January 2017.
Where is Entasis Therapeutics based?
Entasis Therapeutics is based in Waltham, MA.
When did Entasis Therapeutics last raise?
The last disclosed Entasis Therapeutics round closed in January 2017 at Series B.
Entasis Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Waltham below to benchmark round size and investor mix.
